Michael Fichardt (OneBio Venture Studio)

Image for Michael Fichardt (OneBio Venture Studio)

Overview

Michael Fichardt is a South African entrepreneur and the co-founder of OneBio Venture Studio, a pioneering biotech venture builder and investor. Established in Cape Town, OneBio plays a significant role in advancing the biotechnology ecosystem in Africa by supporting early-stage startups. Fichardt's experience in venture capital and technology has been instrumental in the development of numerous biotech firms, demonstrating a commitment to integrating biology with innovative business solutions.

Recent Developments

Recent achievements and efforts related to Michael Fichardt and OneBio Venture Studio include:

  • April 2026: OneBio Venture Studio secured a ZAR 20 million (USD 1.16 million) grant to accelerate its mission of commercializing African biotech research. This funding will enhance OneBio's capacity to support new ventures and expand its operations across key African markets. source

  • 2025: OneBio co-led a pre-seed funding round for Altera Biosciences, raising R29 million (USD 1.6 million) to advance transplant medicine through a universal donor cell platform. source

  • 2024: Portfolio companies LifeQ and CapeBio showed strong commercial promise, with LifeQ raising over USD 47 million in funding across two rounds. This exemplifies the potential scalability and market impact of portfolios supported by OneBio. source

Personal Information

AttributeInformation
Full NameMichael Fichardt
BornSouth Africa
NationalitySouth African
OccupationEntrepreneur, Co-Founder of OneBio Venture Studio
Known ForCo-Founding OneBio Venture Studio, Biotech Investments
EducationMBA from IE Business School; attended Singularity University's Global Solutions Program; Post Graduate Diploma from University of Stellenbosch

Early Life and Education

Michael Fichardt hails from South Africa, where he grew up with a keen interest in science and technology. His educational journey is marked by a strong foundation in business and technology. Fichardt pursued an MBA at IE Business School from 2001-2002, equipping him with comprehensive management and financial skills.

In 2012, he furthered his education with a Post Graduate Diploma in Sustainability and Renewable Energy at the University of Stellenbosch. His commitment to exponential technologies led him to Singularity University in 2015, where he attended the Global Solutions Program. These educational experiences instilled a unique blend of business acumen and technological foresight, shaping his entrepreneurial path.

Career and Notable Achievements

Michael Fichardt's career trajectory is aligned with his entrepreneurial spirit and vision for integrating technology and business:

  • 2015: Co-founded Morpheeo, displaying an early focus on startup creation and innovation.
  • 2016: Became a Director at Glo Ventures, emphasizing strategic venture investments.
  • 2018: Launched OneBio Venture Studio, alongside Nick Walker and Gian-Marco Melfi, to foster biotech startups in Africa. Since its inception, the studio has backed 16 ventures, with a mix of successful exits and other strategic shut-downs, highlighting both risks and opportunities in African biotech.

Current Work and Impact

At present, Michael Fichardt is focused on expanding OneBio's reach across Africa, pioneering biotech innovations through a venture-builder approach. The studio actively builds biotech companies, distinguishing itself by not just funding but also directly creating startups from initial concept stages. This hands-on approach addresses Africa's unique infrastructural challenges, positioning OneBio as a trailblazer in deep tech and biotech innovations across the continent.

Conclusion

Michael Fichardt's impact on the biotech landscape in Africa through OneBio Venture Studio is profound. His strategic vision and commitment to leveraging science for business growth are reshaping the region's approach to biotech startups. As OneBio continues to expand its influence across Africa, Fichardt's legacy will likely be marked by significant strides in integrating biotechnology with sustainable business practices, ultimately contributing to a thriving biotech ecosystem on the continent.